New PNH treatment shows promise in Head-to-Head trial against standard therapy
NCT ID NCT06593938
Summary
This study tested whether a new capsule medication called HRS-5965 works as well as the standard treatment (eculizumab) for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The trial involved 76 patients who took either treatment for 24 weeks. Researchers measured whether the treatments helped improve hemoglobin levels and reduce the need for blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100730, China
-
The Blood Disease Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.